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Abstract 
Purpose 
The aim of the present study was to test the hypothesis that a novel serum 
Helicobacter pylori lgG kit derived from Japanese H. py/oげstrains,namely 
the Sphere Light H. pylori lgG J kit (SしHPJ), would enable discrimination 
of H. pylori infection status. 
Methods 
In al, 273 patients were enrolled in the study and underwent endoscopic 
examination in lnui Clinic of Internal Medicine. Serum H. pylori lgG titers 
were measured using the SL-HP J kit. Current H. pylori infection was 
defined as positivity in at least one H. py/oげtest(rapid urease test, urease 
breath test, monoclonal stool antigen test, or histology), excluding 
serology. Na"lve H. pylori infection was defined as negativity in al H. pylori 
tests and chronic atrophic gastritis (CAG), as determined by endoscopy. 
Previous H. pylori infection was defined as negativity for al H. pylori tests 
despite the presence of CAG. 
Results 
After testing, 134 patients were deemed to be narve to H. pylori infection, 
83 patients were diagnosed with current H. pylori infection, and the 
remaining 56 patients were diagnosed with previous H. pylori infection. 
Median (± quaは1ledeviation) titers in patients with narve, previous, and 
current H. pylori infection were 0.8 ± 0.4, 2.1 ± 2.3, and 24.8 ± 22. 7 U/ml, 
respectively. The receiver operating characteristic (ROC) curve for na"ive 
and previous H. pylori infection to classify na"ive H. py/oげinfectionshowed 
an area under the curve (AUC) of 0.910, with 83% sensitivity and 82% 
specificity for a cut-off level of <1.6 U/ml; the ROC curve for previous and 
current H. pylori infection to classify current H. pylori infection had an AUC 
of 0.969, with 96% sensitivity and 88% specificity for a cuトofflevel ofと3.3
U/ml. 
Conclusions 
The present study shows that serum H. pylori lgG titers may be used to 
determine H. pylori infection status. 
Introduction 
Gastric cancer remains the fifth most common malignancy and the 
third leading cause of cancer death worldwide (1 ). Currently, three East 
Asian countries (Japan, China, and Korea) account for 60% of newly 
detected gastric cancers globally (2). Discovered in 1983, Helicobacter 
pylori infects 50% of the global population. The International Agency for 
Research on Cancer (IARC) classified H. pylori as a definite carcinogen 
for gastric cancer in 1994 (3) and confirmed this in 2009 (1 ). The IARC 
Working Group meeting discussed H. pylori eradication as a strategy for 
preventing gastric cancer in 2013 and recommended that 
population-based H. pylori screening and treatment programs should be 
developed (1 ). 
Serum H. pylori lgG titers are good candidates ・for 
population-based H. pylori screening and treatment programs because 
the tests are non-invasive, inexpensive, convenient, and do not require 
dietary or proton pump inhibitor (PPI) restrictions (4). Serum H. pylori lgG 
titers have sufficient diagnostic accuracy in positive diagnoses. Thus, 
serum H. pylori lgG titers higher than the cuトofvalue can be used to 
diagnose current H. pylori infections. However, serum H. pylori lgG titers 
lower than the cut-off values are indicative of both na'ive and previous H. 
pylori infections. Previous H. pylori infection needs to be distinguished 
from na'ive H. pylori infection because the former is associated with a risk 
of developing gastric cancer (5). To date, commercially available serum H. 
pylori lgG kits, which are widely used in Japan, have a lower limit of 
detection of 3 U/ml. Therefore, currently available serum H. pylori lgG kits 
cannot distinguish previous from na'ive H. pylori infection. 
A novel serum H. pylori lgG kit, the Sphere Light H. pylori lgG J kit 
(SL-HP J; Wako Pure Chemical Industries, Osaka, Japan), has been 
developed from Japanese H. pylori strains with the Cag A antigen and has 
a lower limit of detection (0.2 Ulml) than that of other commercially 
available kits. In the present study we made use of the lower detection 
limit of the novel lgG kit and hypothesized that serum H. pylori lgG titers 
would enable discrimination of previous from na"iVe H. py/oげinfection.
Materials and Methods 
In al, 273 patients with complaints of upper gastrointestinal 
symptoms were enrolled in the study. Al patients underwent endoscopic 
examination at the lnui Clinic of Internal Medicine, Takasaki, Japan, 
between January 2013 and February 2015. Patients with a history of 
gastrectomy, with chronic kidney diseases, or taking steroids or 
antimicrobial agents were not enrolled in the study because these factors 
are likely to affect the diagnosis of H. pylori infection by H. py/oritests and 
endoscopy. In total, 29 patients in whom H. pylori was successfully 
eradicated were included in the study. There were 164 females and 109 
males in the study and the mean patient age was 54.1 years (range 16-94 
years). 
Fasting blood samples were collected for routine laboratory testing 
and were sent to Bio Medical Laboratories (Tokyo, Japan). Serum H. 
pylori lgG titers were measured using the novel serum H. pylori lgG kit 
(SしHPJ; Wako Pure Chemical Industries) derived from the antigens of 
Japanese strains. The kit is a quantitative assay with a lower limit of 
detection of 0.2 U/ml and an upper limit of detection of剖 00U/ml. The 
reproducibility of the titers of a lower limit of detection of 0.2 U/ml has 
been verified. The manufacturer's cut-off value for a positive test is三4.0
U/ml, and the published sensitivity and specificity are 97.1°/o and 97.0o/o, 
respectively (6). Serological testing was pe斤ormedblinded to the results 
of any previous H. pylori tests. 
For endoscopic examinations, an electronic endoscope system 
(Evis Lucera CVL 260SL; Olympus Optical, Tokyo, Japan) with 
narrow司 bandimaging was used. Endoscopic diagnoses were confirmed 
by at least two digestive endoscopic specialists either in real time or 
retrospectively. Regular arrangement of collecting venules (RAC) at the 
gastric angle is a typical sign of being na"ive to H. pyloげinfection(7, 8). 
Conversely, the absence of RAC at the angle or chronic atrophic gastritis 
(CAG) is a finding typical of current or previous H. pylori infection. 
Current H. pylori infection was defined as positivity in at least one H. 
PYわritest (rapid urease test [PyloriTek; Eisai, Tokyo, Japan], urease 
breath test [UBIT; Otsuka Pharmaceutical, Tokyo, Japan], monoclonal 
stool antigen test [Fujirebio, Tokyo, Japan], o「histology),excluding 
serology. Na・ive H. pylori infection was defined as negativity in al H. pylori 
tests and CAG by endoscopy. Previous H. pylori infection was defined as 
negativity for al H. pylori tests despite the presence of CAG (9). Patients 
with previous H. pylori infection were divided into the following two groups: 
(i) those with successful H. pylori eradication (post-H. pylori eradication); 
and (i) those with natural loss of H. pylori as a result of severe atrophy O「
intestinal metaplasia secondary to either unintended use of antibiotics or 
unknown reasons. 
Ethics 
Written informed consent was obtained from al patients prior to 
enrolment in the study. The study was approved by the Institutional 
Review Board of Hokkaido University Hospital (010・0168).
Statistical analyses 
Analyses were performed using JMP 10 (SAS Institute, Cary, NC, 
USA), with P < 0.05 taken to indicate statistical significance. A receiver 
operating characteristic (ROC) curve was generated for each serum H. 
pylori lgG result. 
Results 
Of 273 patients, 134 (49目1% ) were deemed na"lve to H. pylori 
infection and negative fo「CAG.Of the 139 patients positive for CAG, 83 
(30.4%) were diagnosed with current H. pylori infection. The remaining 56 
patients (20.5%) were diagnosed with previous H. pylori infection, 
including 29 in whom H. pylori had been eradicated. The median （土
qua附ledeviation [QD]) time from H. pylori eradication was 3. 7 ± 2.4 years 
(range 1-15 years). 
H. pylori infection status and serum H. pylori lgG titers 
In al patients in whom H. pyloげ hadbeen eradicated, the 
manufacturer's cut-off level ofと4.0U/ml revealed that 5.0% patients were 
narve to H. pylori infection and 17.0% patients had had previous H. pylori 
infection. In contrast, using the manufacturer's cut-off level of <4.0 U/ml 
revealed that 2.9% of patients had current H. pylori infection and 22.5°/o of 
patients had had previous H. pylori infection (Table 1 ). Of the 2.9o/o 
patients with current H. pylori infection, progression of atrophy accounted 
for 60% of cases. A cut-off value of注4.0U/ml for current H. pylori 
infection had a sensitivity and specificity of 94.0°/o and 88.4°/o, 
respectively. 
Serum H. py/oげlgGtiter according to H. py/oげinfectionstatus 
The median (± QD) titers in patients with na"ive, previous, and 
current H. pylori infection were 0.8 ± 0.4, 2.1 ± 2.3, and 24.8 ± 22. 7 U/ml, 
respectively (Figure 1 ). Moreover, the interquartile ranges of the raw data 
did not overlap among groups. These results indicate that the H. pylori 
lgG kit can distinguish al three H. pylori infection states without the need 
for other H. pylori tests. In patients with previous H. pylori infection, the 
median (± QD) lgG titer post-H. pylori eradication was 1.5土 1.0U/ml, 
whereas in patients in whom H. pylori had been naturally lost, the median 
titer was 2.7 ± 3.2 U/ml (Figure 2). 
ROC curve analysis for na"fve and current H. pylori infection 
The ROC curve for na"ive and previous H. pylori infection to classify 
na"ive H. pylori infection showed an area under the curve (AUC) of O目910
(95% confidence interval [Cl] 0.876ー0.945),with 83o/o sensitivity and 82°/o 
specificity for a cut-off level of <1.6 U/ml (Figure 3). Further, the ROC 
curve for previous and current H. pylori infection to classify current H. 
pylori infection had an AUC of 0.969 (95°/o Cl 0.945-0.993), with 96o/o 
sensitivity and 88°/o specificity for a cut-off level of注3.3U/ml (Figure 4). 
Discussion 
In the present study we showed that the H. pyloげ lgGtiter 
determined using the SL-HP J test enabled discrimination among na'ive, 
previous, and current H. pylori infection, suggesting its feasibility as a 
screening tool. An lgG titer of注3.3U/ml indicates current H. pylori 
infection, whereas an lgG titer of <1.6 U/ml indicates naivety to H. pylori 
infection. 
The results of the present study are limited by the small number of 
cases and the fact that al patients had symptoms; thus, a larger-scale 
study involving healthy counterpa吋smay be needed to determine whether 
novel serum H. pylori lgG titers can be used as a screening tool. The 
novel serum H. pylori lgG assay used in the present study exhibited 
higher sensitivity, as demonstrated by a 10-fold lower limit of detection, 
than kits currently widely used in Japan. Therefore, future serum H. pylori 
lgG titer assay kits should have an increased sensitivity to reduce the 
lower limit of detection to distinguish among patients with na'ive, previous, 
or current H. py/oげfinfection目
Kato et al. (8) repo吋edthat H. pylori seroconversion after 
eradication occurs after <:24 months. Moreover, serum lgG to H. pylori 
Cag A antigen persists for a long time after H. pylori disappearance (10), 
in some cases for several decades. According to Veijola et al. (11 ), 
anti-Cag A lgG levels decrease only slightly after a number of years, and 
87% of patients remain positive after 10 years. In the present study we 
showed that the antibody titer of patients with previous H. pyloげinfection
is higher than that of patients na"fve to H. pylori infection, although the 
antibody titer after H. pylori disappearance may decrease over time to 
below the limit of detection. The median duration of patients exhibiting H. 
pylori eradication in the present study was 3.4 years (range 1-15 years). 
The reason why lgG titers in patients with incidental eradication or natural 
loss of H. pylori were higher than in patients with eradication as a result of 
treatment is unclear. One possibility is that patients with incidental 
eradication or natural loss of H. pylori included false-negative results 
because of a decreased bacterial load in the stomach following treatment 
(10). PPls are widely used for long-term treatment of symptomatic 
dyspepsia or gastroesophageal reflux disease. Patients taking these 
medications are negative for H. pylori according to the rapid urease test, 
UBIT, and stool antigen test. The use of PPls causes mucosal changes in 
the stomach by increasing gastric pH. Particularly in the antrum, 
decreases in bacterial load can lead to false-negative results in H. pylori 
diagnostic tests, but do not affect serology. Because interviews conducted 
before the study cannot reveal al information regarding the patients and 
their use of medications, these cases may have included patients in whom 
H. pylori was incidentally eradicated or naturally lost. This issue should be 
resolved in a future larger回scalestudy that includes other H. pylori culture 
or polymerase chain reaction tests for Cag A. 
The sensitivity and specificity of the novel SL-HP J kit determined 
in the present study were lower than those in previous reports that used 
the manufacturer’s cut-off level (6). In the present study, patients with 
titers lower than the manufacturer’s cut-o仔level(4.0 U/ml) included 2.9o/o 
with current H. pylori infection and 22.5% with previous H. pylori infection. 
Several factors could explain why patients with current H. pylori infection 
had lower lgG titers than the manufacturer's cut-off level. Decreased 
mucosal bacterial load due to H. pylori eradication treatment, the 
unintended use of antibiotics, progression of atrophy, or long-term PPI 
use result in decreased serum H. pylori lgG titers. Of these causes, 
progression of atrophy accounted for 60% of cases in the present study. 
No study has evaluated serum H. pylori lgG levels a仕e「long-termuse of 
PP ls, which may also affect the accuracy of serological tests. 
It should be noted that the incidence of gastric cancer in patients 
seronegative for H. pylori was 2o/o (12), compared with 0.66% in those 
without H. pylori infection (13). This difference is likely due to the inclusion 
of current or previous H. pylori司infectedsubjects with negative serological 
test results. H. pylori eradication or incidental eradication has the potential 
to prevent gastric cancer, although these patients remain at risk of 
developing gastric cancer (14）目 Patientswith previous H. pylori infection, 
including those in whom ithas been eradicated, incidentally eradicated, or 
lost naturally (10, 15, 16), were likely included in the study. Forty percent 
of patients with previous H. pylori infection in the present study 
experienced incidental eradication or natural loss of H. pylori目 Thismay 
have resulted in cases of gastric cancer being missed. 
Patients with previous H. pylori infection would be included in the H. 
py/oげscreeningand treatment programs recommended by the IARC. 
Therefore, an accurate diagnosis of previous and current H. pylori 
infections is important. The kits used the present study had a lower limit of 
detection of 0.2 U/ml. The findings show that determining H. pylori lgG 
titers enabled discrimination of na"fve, previous, and current H. pylori 
infection. Determination of serum H. pylori lgG titers enabling 
discrimination of the H. pylori infection status is necessary for 
population-based H. py/oげ screening and subsequent treatment 
programs. 
Conclusions 
The present study has shown that serum H. pylori lgG titers may be 
used to distinguish among na"ive, current, and previous H. pylori infection 
status. 
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Figure 1. Serum He/icobacter pylori lgG antibody titer according to H. 
pylori infection status目 Boxesrepresent the interquartile range of antibody 
titers, with the median indicated by the horizontal line. Whiskers indicate 
maximum and minimum values. 
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Figure 2. Serum Helicobacter pylori lgG antibody titers in patients with 
previous H. pylori infection according to mode of loss of infection. Boxes 
represent the interquartile range of antibody titers, with the median 
indicated by the horizontal line. Whiskers indicate maximum and minimum 
values目
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Figure 3. Receiver operating characteristic (ROC) curve analysis for 
patients with na・1ve and previous He/icobacter pyloげinfectionto classify 
na'lve H. pyloげinfection.Cl, confidence interval; AUC, area under the 
curve. 
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Table 1. Helicobacter pylori infection status according to serum H. py/oげ
lgG antibody titers 
Infection status 
Na"ive 
Previous 
Current 
;:4_0 
5 (5.0) 
17 (17.0) 
78 (78.0) 
Titer (U/ml) 
<4.0 
129 (74.6) 
39 (22.5) 
5 (2.9) 
Data show the number of patients in each group, with percentages in 
parentheses. 
The manufacturer's cut-off level of三4.0U/ml revealed that 5.0% of 
patients were na"ive to H. pylori infection and that 17.0°/o of patients had 
had previous H. pylori infection. In contrast, the manufacturer’s cut-o仔
level of <4.0 U/ml revealed that 2.9% of patients had current H. pylori 
infection and that 22.5% had had previous H. pylori infection. 
